# DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Source: https://onco.cc/trials/nct07070440/  
OnCo record `nct07070440` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pemetrexed, Carboplatin, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.

## Summary

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) is a phase 1/2 interventional study registered as NCT07070440 by Dizal Pharmaceuticals, with 180 participants planned, started 2025-07-16 and due to reach its primary completion in 2027-06. Interventions recorded: DZD6008, Pemetrexed, Carboplatin, Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07070440
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07070440: https://clinicaltrials.gov/study/NCT07070440

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07070440.json